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Abstract
Aims: The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen
19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response, time
to progression (TTP) and overall survival (OS).
Methods: Analyses were derived from three consecutive gemcitabine-containing phase II clinical trials
between 1997 and 2004.
Results: A total of 111 patients with pancreas cancer was studied. Baseline CA19-9 concentrations were
dichotomized near the median. Lower baseline CA19-9 levels were positively associated with OS (median
9.1 vs 6.1 months, P = 0.0057) and TTP (median 6.4 vs 4.2 months, P = 0.0044).The covariate adjusted
hazard ratio (HR) for progression among patients with baseline CA19-9  1000 ng/mL was HR = 1.94
(95% CI 1.24–3.02), with P = 0.0035. The covariate adjusted risk of death among patients with baseline
CA19-9  1000 ng/ml was similarly elevated: HR = 1.90 (95% CI 1.23–2.94), with P = 0.0039. Change in
CA19-9 levels from baseline to the end of treatment cycle 1 did not predict objective response (P = 0.75).
There was somewhat longer OS (median 8.7 vs 7.1 months) and TTP (median 7.1 vs 5.4 months) in patients
with 50% reduction in serum CA19-9 concentrations, but this was not statistically significant (P = 0.74
and 0.81, respectively).
Conclusion: Baseline CA19-9 levels may predict survival in patients with advanced pancreas cancer. The
change in CA19-9 levels determined within 1 month of the initiation of therapy did not predict treatment
outcome.
Key words: CA19-9, gemcitabine, pancreatic cancer.
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer
death in the USA. The 5-year survival rate is generally
less than 5%.1 The mainstay of treatment of locally
advanced and metastatic pancreatic cancer is chemo-
therapy. Gemcitabine, the most active chemotherapeutic
agent in pancreatic cancer, has shown a clinical benefit
response rate of 24% and a survival rate at 1 year of
18%.2 A major challenge in the optimum delivery of
therapy to patients with pancreatic cancer is the objec-
tive evaluation of tumor response, including the lack of
predictive biomarkers.3 Response evaluation by cross-
sectional imaging is limited by the anatomic location of
the pancreas and the marked fibrosis that surrounds
tumor cells. Efforts are underway to develop alternative
methods of evaluating response to guide earlier treat-
ment decisions. This would help to avoid futile therapy
and improve the risk stratification of patients in clinical
trials.
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The carbohydrate antigen 19-9 (CA19-9) is the most
widely used serum tumor marker in pancreatic cancer,
and was first described in 1979.4 The epitope of this
antibody was subsequently identified as a sialylated
lacto-N-fucopentaose II related to the Lewisa blood
group antigen. Approximately 5% of the general popu-
lation is genotypically Lewisa-b- and do not express
CA19-9 because of an inherited deficiency of a fucosyl-
transferase specified by the Le gene.5 Approximately
15–20% of pancreatic cancer patients will not have an
elevated CA19-9 at baseline. Pre-operative CA19-9 levels
have been shown to predict recurrence and survival in
patients with resected pancreatic cancer but at the time of
writing do not influence the decision to operate.6
Serial measurements of serum CA19-9 levels in
patients undergoing systemic therapy are used as
adjuncts for evaluating response. However, it is not
known what magnitude of change from the baseline
level might be associated with radiological tumor
response. Moreover, an early measurement of CA19-9
after one cycle of therapy may be a surrogate marker for
a subsequent radiological response, which is usually
evaluated after the second or third cycle of therapy. The
aim of this study was to determine the role of baseline
CA19-9 measurements and their change following the
first cycle of gemcitabine-based therapy as potential pre-
dictors of tumor response, time to progression (TTP),
and overall survival (OS).
METHODS
Patients
This study was an analysis of prospectively collected
data pooled from three phase II studies examining gem-
citabine and cisplatin alone or in combination with
other agents. All three studies were undertaken at the
Karmanos Cancer Institute in Detroit and the University
of Michigan in Ann Arbor. The three trials are described
in Table 1 and are all published. Patients were previ-
ously untreated with gemcitabine or any other chemo-
therapy except for their advanced disease.
To be eligible for these studies the patients must have
had a histological or cytological diagnosis of pancreatic
adenocarcinoma (locally advanced or metastatic). The
patients were required to have a Southwest Oncology
Group performance status of 0 to 2, a life expectancy
of at least 3 months and adequate hematologic, renal
and hepatic function. Exclusion criteria were fairly
uniform across the three studies and included preg-
nancy, active malignancy within the preceding 5 years
except for adequately treated basal cell, squamous cell
skin cancer, or in situ cervical cancer. All patients pro-
vided a signed informed consent in accordance with the
institutional Human Investigational Committee guide-
lines prior to enrollment in the study. Serum CA19-9
was obtained at baseline and after each cycle of treat-
ment. For patients with elevated bilirubin at presenta-
tion who underwent biliary stenting, CA19-9 level after
normalization of serum bilirubin was considered as the
baseline.
Statistical methods
Descriptive statistics were used to summarize patient
characteristics and response rates. Exact 90% confi-
dence limits for response proportions utilized the
Casella method7 and were computed in StatXact.8
Response rates were compared via Fisher’s exact test.
Responses were determined according to the World
Health Organization criteria for the earlier two studies,
and by Response Evaluation Criteria in Solid Tumors
criteria in the most recent third study. TTP was defined
as the time from study registration until computed
tomography (CT) documentation of disease progression
or death, whichever came first. Patients who were pro-
gression free were censored as at the last date of
their tumor assessment. OS was defined as the time
from study registration until death from any cause, with










at baseline and after one
cycle of chemotherapy
Gemcitabine and cisplatin20 May 1997 to March 1999 42 40 30
Gemcitabine, cisplatin and 5-FU21 April 1999 to November 2001 47 43 27
Gemcitabine, celecoxib and cisplatin22 January 2002 to May 2003 22 19 11
Total 111 102 68
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censoring of patients still alive as at the last date that
was determined by any method. Standard Kaplan–Meier
estimates of the censored TTP and OS distributions were
computed. Due to the modest sample sizes, survival
statistics (e.g. median, and confidence interval [CI] esti-
mates) were estimated more conservatively using a
linear interpolation9 among successive event times on
the Kaplan–Meier curves. Censored TTP and OS distri-
butions were compared using the log–rank test.9
Multivariable Cox proportional hazard (PH) regres-
sion models10 were used to examine the association of
(median-dichotomized) baseline CA19-9 (<1000 ng/mL
vs 1000 ng/mL) with TTP. The model controlled for
the following covariates: stage (locally advanced, meta-
static), race (black, white) and age group (<56 years,
56+ years). The statistical strength of associations
between every pair of candidate predictors was exam-
ined via Fisher’s exact test. If near colinearity was indi-
cated, only one of those covariates was used in the
multivariable Cox modeling. That occurred for perfor-
mance status (PS) and CA19-9 dichotomy, hence we
could not adjust for PS as a covariate. The PH assump-
tion was tested by including an interaction (product
term) of each independent variable with the natural
logarithm of TTP. PH was accepted if that interaction
term was not significant (P > 0.05).11 There was no evi-
dence of significant non-PH in TTP for any of the pre-
dictor variables. First order statistical interactions
between baseline CA19-9 dichotomy and each of the
three covariates listed above were also examined in the
Cox models. Hence, the initial model included five main
effects and four interaction terms. One significant inter-
action term was detected (sex with CA19-9 group), so
sex was used as a stratification variable in a subsequent
Cox model. The other interaction terms were dropped
and a four-variate main effects only, sex-stratified model
was refitted.12 Goodness of fit of the final Cox model of
TTP was evaluated using plots of deviance residuals.11 A
completely analogous Cox modeling investigation was
performed for OS and resulted in the same four-variate
main effects only, sex-stratified final model.
RESULTS
Table 1 summarizes the three clinical trials with respect
to chemotherapy regimen, accrual time period and
population size. There were no statistically significant
differences across the three trials in CA19-9 levels,
either at baseline or after the first cycle of
chemotherapy.
Patients’ characteristics
Table 2 summarizes the baseline characteristics of 111
patients from these three clinical trials. The median age
was 56 years. The median PS was 1 (range 0–2). No
significant difference was observed across the three trials
with respect to age, sex or PS. Race (in three groups)
differed significantly by trial (P = 0.0287), but not by
race in two groups (African Americans, Caucasian:
P = 0.1367). Overall 18% of patients had locally
advanced pancreatic cancer. Stage differed significantly
by trial (P = 0.0004), presumably because the most
recent trial was restricted to metastatic patients. To
control for any possible residual confounding by stage
or race those two covariates were included in the mul-
tivariable Cox models of TTP and OS.
For all the patients the overall response rate (complete
response + partial response) was 21% (23 of 111, 90%
CI 0.15–0.28). Median TTP and OS were 5.6 months
(90% CI 4.4–6.7 months) and 7.8 months (90% CI 6.8–
8.9 months), respectively.
Relationship between the baseline CA19-9
levels and treatment outcomes
The baseline CA19-9 measurement was available for
102 patients. It was dichotomized near the median as
<1000 vs 1000 ng/mL, as in other studies.13 There
were 49 patients with baseline CA19-9 < 1000 ng/mL
and 53 patients with CA19-9  1000 ng/mL. Respon-
serates did not differ significantly between patients in the
lower versus the higher baseline CA19-9 categories
(22% vs 19%, respectively; P = 0.82).
Table 2 Patient characteristics (N = 111)
Characteristics Number Percentage













Locally advanced 20 18
Metastatic 91 82
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The median TTP for patients in the lower and upper
halves of baseline CA19-9 was 6.4 and 4.2 months,
respectively (see Fig. 1). TTP was statistically signifi-
cantly different between the two groups (P = 0.0044).
Median OS for patients in the lower and upper halves of
baseline CA19-9 was 9.1 and 6.1 months, respectively
(Fig. 2). From a univariate Cox model of TTP, the HR
for progression among patients with high (above
median) baseline CA19-9 was 1.82 (95% CI 1.20–2.77,
P = 0.0049). This association persisted after adjustment
for stage, race and age group in a sex-stratified Cox
model of TTP which yielded HR = 1.94 (95% CI 1.24–
3.02, P = 0.0035).
OS was statistically significantly different between
these two groups (P = 0.0057). The 1-year survival rate
was 38% for patients with CA19-9 < 1000 ng/mL and
15% for patients with CA19-9  1000 ng/mL. From a
univariate Cox model of OS, the HR for death among
patients with high (above median) baseline CA19-9 was
1.77 (95% CI 1.18–2.67, P = 0.0062). This association
persisted after adjustment for stage, race and age group
in a sex-stratified Cox model of OS which yielded
HR = 1.90 (95% CI 1.23–2.94, P = 0.0039).
Predictive role of CA19-9 after first cycle
of chemotherapy
Of the 102 patients with available pretreatment CA19-9
levels, the CA19-9 measurement after the first cycle of
chemotherapy was available for 68 patients. Of those 68
patients, one patient had disease progression within the
first month of enrollment and was excluded from analy-
ses. The effective sample size was 67 for response and
TTP and 68 for OS. Patients were divided according to
the magnitude of decrease (yes/no) in CA19-9 after the
first cycle of chemotherapy using the three cut-off points
1%, 20% and 50%. Of the 67 patients, 46 had
1% decline, 34 had 20% decline and 17 had 50%
decline.
No significant difference in response rate was
observed between those who had a decline in CA19-9
after the first cycle of chemotherapy and those who did
not, irrespective of the magnitude of decline (Table 3).
The largest difference occurred among patients who had
a 20% decrease in CA19-9, with 34 patients having a
29% response rate compared to a 21% response rate
among the 33 patients showing either smaller decreases
or actual increases in CA19-9. However, this difference
in response rates was not statistically significant. For the
31 stable disease (SD) patients, the median change in
CA19-9 was -18.9%, that is, a decrease. Thus, almost
half of the SD patients achieved 20% decline in their
CA19-9 level.
Patients with a decrease in CA19-9 after the first cycle
of chemotherapy had only slightly longer TTP than did
patients without such a decrease. Patients who had no
decrease in CA19-9 had the worst disease progression
Figure 1 Kaplan–Meier graph of
time to progression (TTP) by category
of baseline carbohydrate antigen 19-9
(CA19-9) at levels (——) <1000 and
(------) >1000. For the 49 patients
with baseline CA19-9 < 1000 ng/mL,
median TTP was 6.4 months (90% CI
5.1–8.2) and their 1-year progression-
free rate was 20% (90% CI 0.09–
0.32). For the 53 patients with baseline
CA19-9 > 1000 ng/mL, the median
TTP was 4.2 months (90% CI 2.6–5.6)
and their 1-year progression-free rate
was 7% (90% CI 0.00–0.15). Log–
rank test P = 0.0044. Of the 102
patients with a baseline CA19-9 mea-
surement, 96 had progressed.
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outcome (median TTP 3.9 months, with a lower 90%
confidence limit of 1.9 months).
Overall survival was not significantly different
between patients who demonstrated a decline in CA19-9
and those who did not, although it was slightly longer
for those who did experience a decline. The best survival
outcome was seen among those who had at least a 50%
decrease in CA19-9 (median OS 8.7 months). Patients
who had less than 1% decrease or actual increase had
the worst OS (median 6.5 months).
Since no significant univariate association was found
between any magnitude of decrease in CA19-9 and any
of our three endpoints, no multivariable modeling of
these associations was necessary.
DISCUSSION
The prognosis of patients with locally advanced or
metastatic pancreatic cancer remains dismal. The impact
of modern therapies including targeted agents remains
Figure 2 Kaplan–Meier graph of
overall survival (OS) by category of
baseline carbohydrate antigen 19-9
(CA19-9) at levels (——) <1000 and
(------) >1000. For the 49 patients with
baseline CA19-9 < 1000 ng/mL the
median OS was 9.1 months (90% CI
7.0–11.9) and the 1-year survival rate
was 38% (90% CI 0.25–0.52). For the
53 patients with baseline CA19-
9 > 1000 ng/mL the median OS was
6.1 months (90% CI 4.5–7.7) and the
1-year survival rate was 15% (90% CI
0.05–0.24). Log–rank test P = 0.0057.
Of the 102 patients with a baseline
CA19-9 measurement, 97 had died.
Table 3 Comparison of response rate, time to progression, and overall survival by dichotomy of percentage change in carbohy-
drate antigen 19-9 (CA19-9) after the first cycle of gemcitabine-based chemotherapy
Size of decrease in CA19-9 Yes† No P-value‡§
1% decrease N = 46 N = 21
Response, n (%) 12 (26%) 5 (24%) 1.00
Median TTP (months) (90% CI) 6.3 (5.4–7.3) 3.9 (1.9–6.9) 0.36
Median OS (months) (90% CI) 8.2 (6.9–10.1) 6.5 (4.7–8.7) 0.14
20% decrease N = 34 N = 33
Response, n (%) 10 (29%) 7 (21%) 0.58
Median TTP (months) (90% CI) 6.5 (6.0–7.4) 3.9 (3.1–6.9) 0.83
Median OS (months) (90% CI) 8.5 (7.0–10.2) 6.7 (4.6–8.6) 0.55
50% decrease N = 17 N = 50
Response, n (%) 5 (29%) 12 (24%) 0.75
Median TTP (months) (90% CI) 7.1 (5.5–7.6) 5.4 (3.3–6.4) 0.81
Median OS (months (90% CI) 8.7 (7.1–10.3) 7.1 (6.6–8.4) 0.73
†For OS only, N = 47, 35, and 18 for Yes patients in the three successive dichotomies, respectively; ‡From Fisher’s exact test for comparison of
response rates; §From log–rank test for comparison of time to progression (TTP) and overall survival (OS). CI, confidence interval.
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very modest. It may be important to assess response
to chemotherapy early in the course of treatment in
order to guide treatment decisions and offer prognostic
information. The CA19-9 response has emerged as a
potential surrogate marker for evaluating the patient’s
response to chemotherapy. The present study focuses
on the association of pretreatment CA19-9 with the
outcome for patients with advanced pancreas cancer as
well as the relationship between the change in CA19-9
concentrations at the completion of first cycle of
therapy prior to radiological evaluation and outcome
with respect to response, TTP and survival. The goal of
this analysis was to evaluate the predictive role of CA
19-9 for treatment, especially early in the course of
therapy.
There was a statistically significant difference in TTP
and OS in patients with the lower baseline CA19-9
levels using a cut-off point of 1000 ng/mL. This relation-
ship could not be accounted for by the simultaneous
adjustment for stage, race and age group in multivari-
able Cox models. Saad et al. retrospectively analyzed
the pre-treatment CA19-9 levels in 28 patients with
advanced pancreatic cancer treated with gemcitabine.
They found that patients who had CA19-9 below the
median for the entire sample (1212 U/mL) survived
twice as long as those with a CA19-9 above the median
(14.9 vs 7.4 months, P = 0.0013). In multivariable
analysis, baseline CA19-9 level was an independent and
stronger predictor of survival than CA19-9 decline on
therapy.14 Maisey et al. examined the significance of
baseline CA19-9 in 154 patients treated with both gem-
citabine and 5-fluorouracil or with single agent
5-fluorouracil. OS in patients with a baseline CA19-9
below the median value (958 U mL-1) was significantly
longer than OS in patients with levels above the median.
The 1-year OS rates were 46% and 19%, respectively,
for patients with a baseline CA19-9 below the median
value versus those with a baseline CA19-9 above it.13
Our study confirms the findings of a positive association
between lower baseline CA19-9 concentration and OS.
CA19-9 levels may therefore be used as a stratification
factor in randomized clinical trials.
Recent reports have examined the role of CA19-9
response to gemcitabine and the kinetics of CA19-9 as
a surrogate of the response to such treatment. Most
studies determined the change from baseline at a sub-
sequent point of approximately 8 weeks. This coincided
with two cycles of therapy, which is often a time when
imaging tests will be performed. Halm et al. examined
43 patients with locally advanced or metastatic pancre-
atic cancer treated with gemcitabine, and demonstrated
that a >20% decrease in baseline CA19-9 level after
8 weeks of treatment was associated with a longer
median survival than a rise or a <20% decrease in the
baseline CA19-9 level.15 Rocha Lima et al. studied
CA19-9 responses in 44 patients with advanced pancre-
atic cancer treated with gemcitabine and irinotecan.
A strong correlation between CA19-9 progression
(defined as a greater than 50% increase in CA19-9
when the lowest on-study level was 200 ng/mL or lower
or a greater than 25% increase in CA19-9 when the
lowest level was higher than 200 ng/mL) and TTP
(r = 0.89, P < 0.001), with CA19-9 progression preced-
ing radiographic progression in most patients.16 Ziske
et al. studied the CA19-9 response in 46 patients with
locally advanced or metastatic pancreatic cancer and
found that those with a decrease in CA19-9 levels
of >20% from the baseline level after 8 weeks of che-
motherapy had a significantly longer survival than
patients with a rise or decline <20%. The response of
CA19-9 > 20% during chemotherapy was the only
independent predictor of survival in multivariable
analyses. In contrast, neither an objective tumor
response nor a clinical benefit response showed this
level of association.17 Stemmler et al. prospectively
studied the kinetics of CA19-9 in patients with locally
advanced or metastatic pancreatic cancer treated with
gemcitabine and cisplatin and found that, independent
of the response evaluation by CT imaging, CA19-9
responders (defined as patients achieving 50%
decrease in CA19-9 serum levels within 2 months after
treatment initiation) survived significantly longer than
CA19-9 nonresponders. Median survival was 295 days
versus 174 days, respectively.18 Ko et al. retrospectively
evaluated the decline in CA19-9 in 76 patients with
advanced pancreatic cancer receiving a fixed dose rate
of gemcitabine pooled from three separate studies. They
found statistically significant associations between the
percentage of CA19-9 decline and both OS and time to
treatment failure. Median OS was 12 months for the
patients with a >75% decline in CA19-9, and only
4.3 months for the patients who did not achieve any
decline at all. In their study, the decline in baseline
CA19-9 was defined as occurring at any point in time
after the initiation of treatment, whether early or late,
and is counted as biomarker response, although a sig-
nificant proportion of patients who responded did so
within the first 2 months of therapy.19
The early (4 weeks) determination of response to
therapy is beneficial in clinical trials when the prolonged
use of a futile experimental drug can be avoided in a
patient. In the present study the CA19-9 response after
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the first cycle of chemotherapy was investigated.
Patients with 50% decline in CA19-9 after the first
cycle of chemotherapy had a higher response rate,
though it was not statistically significant, than did
patients with no decline or with an actual increase. TTP
and OS were longer for patients with 50% decline
after cycle 1 but not statistically significantly so. There-
fore, a 50% decline in CA19-9 after the first cycle
ofchemotherapy was not a useful predictor of response,
TTP or OS in our study.
There are several possible explanations for the
failure to demonstrate the prognostic significance of
CA19-9 very early in the course of treatment: (i) the
short natural history of locally advanced and meta-
static pancreatic cancer may make it difficult to show
the impact of a tumor marker that can reliably assess
response very early in the course of treatment; (ii) poor
treatment alternatives rather than the adequacy of
the marker itself; and (iii) the small sample size, as a
larger sample size may be required to show such an
effect. Even though a change in CA19-9 after the first
cycle of chemotherapy was not useful, the pattern of
change over time, especially in the face of SD radio-
graphically, may provide valuable information to guide
therapy.
Studies on the validation of biomarkers in patients
with cancer face several challenges. One limitation to
this analysis may be the inclusion of three different trials
with different chemotherapeutic regimens. However, all
three trials were gemcitabine-based. Another limitation
is the influence of biliary obstruction on the concentra-
tions of CA19-9 in serum. This factor was not consid-
ered in data analysis. This is especially a problem for
using early (4 weeks) time points to establish predic-
tive biomarkers because of the impact of biliary tract
pathology or interventions, or both, that would falsely
elevate CA19-9 levels. A strength of this investigation is
its prospective nature and the fact that these trials were
conducted in only two institutions, which provides uni-
formity in the treatment and quantification of CA19-9.
Furthermore our study used rigorous statistical model-
ing that revealed a statistically significant relationship
of baseline CA19-9 level to TTP and to OS, even
after simultaneous adjustment for stage, race and age
group.
In conclusion, our study supports the hypothesis that
baseline CA19-9 has significant prognostic value in
patients with metastatic or locally advanced pancreatic
cancer. Its incorporation into the baseline risk stratifica-
tion should be considered in future therapeutic studies,
especially in the randomized setting.
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